Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group (Q74594698)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 March 1999

Language	Label	Description	Also known as
English	Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group	scientific article published on 01 March 1999

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10071916%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10071916%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10071916%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

author name string

B Clemmesen

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10071916%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

C Christiansen

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10071916%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

publication date

1 March 1999

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10071916%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10071916%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

24

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10071916%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10071916%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

237-244

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10071916%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900183-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900183-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900183-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900183-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900183-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900183-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900183-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Noninvasive assessment of bone mineral and structure: state of the art.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900183-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900183-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Bisphosphonate effects and the bone remodeling transient.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900183-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900183-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900183-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900183-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900183-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900183-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of postmenopausal bone loss by tiludronate

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900183-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900183-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S8756-3282(98)00183-5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10071916%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10071916%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q74594698&oldid=2105030448"